(Q24234081)

1

Alpo Vuorio

0 references

Petri T Kovanen

3

Petri T Kovanen

0 references

Jaana Kuoppala

2

Jaana Kuoppala

0 references

Serena Tonstad

6

Serena Tonstad

0 references

Timo Strandberg

5

Timo Strandberg

0 references

Helena Gylling

7

Cochrane Database of Systematic Reviews

Helena Gylling

0 references

publication date

7 July 2010

0 references

published in

0 references

cites work

Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Early statin therapy restores endothelial function in children with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Long-term treatment with atorvastatin in adolescent males with heterozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Efficacy and safety of pravastatin in children and adolescents with heterozygous familial hypercholesterolemia: a prospective clinical follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Statin safety: an overview and assessment of the data--2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Adverse effects of statins - mechanisms and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

An assessment of statin safety by neurologists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Statin-associated peripheral neuropathy: review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Statins and liver toxicity: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Regulation of the mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Genetic screening protocol for familial hypercholesterolemia which includes splicing defects gives an improved mutation detection rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Relation of peripheral flow-mediated vasodilatation and coronary arterial calcium in young patients with heterozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Drug treatment of lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Statin safety: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Development of coronary heart disease in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Dietary treatment for familial hypercholesterolaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Statin treatment in children with familial hypercholesterolemia: the younger, the better

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Cerivastatin and reports of fatal rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Familial hypercholesterolaemia in Finland: common, rare and mild mutations of the LDL receptor and their clinical consequences. Finnish FH-group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

7 January 2021

The effect of low-dose simvastatin in children with familial hypercholesterolaemia: a 1-year observation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

7 January 2021

Lack of effect of probucol on atheroma formation in cholesterol-fed rabbits kept at comparable plasma cholesterol levels

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

7 January 2021

Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

7 January 2021

Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia. The Familial Hypercholesterolaemia Regression Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

7 January 2021

Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

7 January 2021

Diagnosing familial hypercholesterolaemia in childhood

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

7 January 2021

Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

7 January 2021

ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006401.PUB2

7 January 2021